Literature DB >> 9704065

G-protein coupled receptor-mediated activation of PI 3-kinase in neutrophils.

M Thelen1, S A Didichenko.   

Abstract

Stimulation of the respiratory burst of neutrophil leukocytes with chemotactic agonists requires two concomitant signal transduction pathways. One is calcium dependent and leads to activation of phospholipase C, the other is calcium independent but sensitive to the fungal metabolite wortmannin, a specific inhibitor of phosphatidylinositide 3-kinase (PI 3-kinase). Two isoforms of PI 3-kinase have been characterized in neutrophils, the p85/p110 PI 3-kinase alpha and the p101/p120 PI 3-kinase gamma. The relative contribution of the two PI 3-kinases in mediating chemoattractant-stimulated superoxide production and exocytosis in neutrophils in unclear. Here, we report that the protein tyrosine kinase inhibitor genistein markedly attenuates chemoattractant-stimulated phosphatidylinositol (3,4,5)-trisphosphate (PIP3) formation in neutrophils. PI 3-kinase activity in untreated cells is bimodal showing a maximum production after 10-15 sec that protracts with a lower PIP3 formation for approximately 2 min and returns to basal levels after 2-3 min. Genistein at 100 microM strongly inhibits PIP3 elevation and the fMet-Leu-Phe-stimulated respiratory burst. The activity of purified PI 3-kinase, however, is not altered in the presence of genistein, suggesting that the genistein-sensitive intermediate is located between the G-protein-coupled receptor and PI 3-kinase. Expression of a dominant negative form of PI 3-kinase alpha in GM-1/CXCR1 cells, a promyelolocytic cell line transfected with the G-protein-coupled receptors CXCR1, considerably reduces IL-8-stimulated PIP3 formation. The present observations suggest that in phagocytes stimulated with agonists of G-protein-coupled receptors the bulk of PIP3 is generated by PI 3-kinase alpha, which is activated through a genistein-sensitive target, presumably a protein tyrosine kinase.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9704065     DOI: 10.1111/j.1749-6632.1997.tb46265.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  7 in total

1.  Protein kinase A-dependent and -independent signaling pathways contribute to cyclic AMP-stimulated proliferation.

Authors:  L A Cass; S A Summers; G V Prendergast; J M Backer; M J Birnbaum; J L Meinkoth
Journal:  Mol Cell Biol       Date:  1999-09       Impact factor: 4.272

Review 2.  CXC chemokine signaling in the liver: impact on repair and regeneration.

Authors:  Heather L Van Sweringen; Nozomu Sakai; Amit D Tevar; Justin M Burns; Michael J Edwards; Alex B Lentsch
Journal:  Hepatology       Date:  2011-06-29       Impact factor: 17.425

Review 3.  Mechanisms of the Immunological Effects of Volatile Anesthetics: A Review.

Authors:  Koichi Yuki; Roderic G Eckenhoff
Journal:  Anesth Analg       Date:  2016-08       Impact factor: 5.108

4.  Signaling and cross-talk by C5a and UDP in macrophages selectively use PLCbeta3 to regulate intracellular free calcium.

Authors:  Tamara I A Roach; Robert A Rebres; Iain D C Fraser; Dianne L Decamp; Keng-Mean Lin; Paul C Sternweis; Mel I Simon; William E Seaman
Journal:  J Biol Chem       Date:  2008-04-14       Impact factor: 5.157

5.  Kupffer cells regulate liver recovery through induction of chemokine receptor CXCR2 on hepatocytes after acetaminophen overdose in mice.

Authors:  Nga T Nguyen; David S Umbaugh; Giselle Sanchez-Guerrero; Anup Ramachandran; Hartmut Jaeschke
Journal:  Arch Toxicol       Date:  2021-11-01       Impact factor: 5.153

6.  Arrest Functions of the MIF Ligand/Receptor Axes in Atherogenesis.

Authors:  Sabine Tillmann; Jürgen Bernhagen; Heidi Noels
Journal:  Front Immunol       Date:  2013-05-16       Impact factor: 7.561

7.  Involvement of Akt and endothelial nitric oxide synthase in ventilation-induced neutrophil infiltration: a prospective, controlled animal experiment.

Authors:  Li-Fu Li; Shuen-Kuei Liao; Cheng-Huei Lee; Chung-Chi Huang; Deborah A Quinn
Journal:  Crit Care       Date:  2007       Impact factor: 9.097

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.